Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET
Company Participants
Carlo Tanzi - IR
Eric Shaff - President and CEO
David Arkowitz - CFO
Matthew Henn - Chief Scientific Officer
Lisa von Moltke - Chief Medical Officer
Terri Young - Chief Commercial and Strategy Officer
Conference Call Participants
Mark Breidenbach - Oppenheimer
John Newman - Canaccord Genuity
Chris Howerton - Jefferies
Ted Tenthoff - Piper Sandler
Peyton Bohnsack - Cowen
Chris Shibutani - Goldman Sachs
Keay Nakae - Chardan
Operator
Good morning ladies and gentlemen, and welcome to the Seres Therapeutics Q2 2021 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Dr. Carlo Tanzi of Investor Relations.
Carlo Tanzi
Thank you and good morning. Our press release with the company's second quarter 2021 financial results and the business update became available at 7:00 AM Eastern Time this morning, and can be found on the Investors & News section of the company's website.
I'd like to remind you that we'll be making forward-looking statements relating to the timing, enrollment and results of our clinical studies, the anticipated safety profile of our products, regulatory approval, the success of our agreement with Nestle, the sufficiency and availability of cash to fund operations, and the promise and potential impact of any of our microbiome therapeutics.
Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the Risk Factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so.
On today's call, with prepared remarks, I'm joined
- Read more current MCRB analysis and news
- View all earnings call transcripts